Table 1.

Comparison of baseline characteristics of statin users versus non-statin users

Variables	Statin users				Non-statin users
	Total	Prior	Continued	New
N	1093	268	423	402	1364
Age (years) mean±SD (median)†	65.1±13.6	70.4±12.5	68.2±12.7	58.4±12.5	60.3±15.0
Female	39.7%	41.0%	41.6%	36.8%	43.1%
Race/ethnicity
Black	29.1%	27.2%	23.9%	35.8%	35.2%
Hispanic	32.8%	27.6%	25.3%	44.0%	35.3%
White	38.2%	45.1%	50.8%	20.1%	29.5%
Risk Factors
History of ischemic stroke†	18.0%	25.0%	19.1%	12.2%	8.6%
History of Diabetes†	39.2%	47.0%	48.0%	24.9%	21.5%
History of Alzheimer disease	2.0%	2.2%	3.1%	0.7%	1.7%
History of Dementia (non-Alzheimer)	5.0%	11.2%	5.0%	1.0%	3.8%
History of hypertension†	91.0%	92.2%	94.8%	86.3%	80.4%
History of high cholesterol†	69.7%	88.1%	93.6%	31.8%	27.3%
Prior use of antiplatelet therapy†	10.9%	18.3%	14.2%	2.5%	2.7%
Prior use of anticoagulants†	16.7%	22.8%	24.8%	4.2%	8.4%
Prior moderate use of alcohol†	22.6%	19.4%	22.9%	24.4%	25.6%
ICH Category‡
Lobar	33.5%	43.3%	38.3%	21.9%	29.8%
Deep (Includes Primary IVH)	54.8%	44.4%	49.9%	66.9%	56.4%
Brainstem	4.1%	4.1%	3.3%	5.0%	6.5%
Cerebellum	7.6%	8.2%	8.5%	6.2%	7.3%
Admission GCS (median, IQR) †	15, 12–15	13, 7–15	15, 14–15	15, 13–15	14, 9–15
Initial Hematoma volume* (mean±SD)	20.2±26.7	39.2±39.6	13.7±15.8	13.3±15.3	21.2±24.0
Presence of IVH‡	40.3%	54.5%	36.2%	35.1%	46.2%
Microbleed Present	52.2%	51.6%	41.7%	61.9%	53.7%
Microbleed Location
Lobar only	8.3%	12.5%	13.0%	3.6%	9.4%
Non-Lobar only	16.6%	12.5%	8.1%	24.0%	6.5%
Lobar plus Non-Lobar	27.5%	27.1%	19.5%	33.5%	29.4%
Prestroke mRS†
0	65.0%	52.5%	61.6%	76.8%	74.4%
1	14.2%	15.8%	16.6%	10.7%	9.4%
2	12.0%	16.6%	12.3%	8.7%	7.9%
3	5.1%	9.1%	5.9%	1.7%	4.6%
4	3.1%	5.3%	2.8%	2.0%	2.9%
5	0.5%	0.8%	0.7%	0.0%	0.8%

^*= CT imaging within 6 hours of onset

^†=P<0.0001 (P-values reflect the comparison between statin users and non-statin users).

^‡=p<0.05 ((P-values reflect the comparison between statin users and non-statin users).